Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
The Lausanne University Hospital (CHUV)
has reported the initial dosing of a patient in a phase II clinical study
investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a
cardiovascular and inflammatory setting. It is the first time that Eckert &
Ziegler’s proprietary CXCR4-compound is used in an advanced clinical test in a
non-cancer indication, opening the way for a broader use of PENTIXAFOR outside
of oncology.
To read more please visit:
Lausanne
University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
Source: Eckert&Ziegler